GlassScriptPhysician profile
Whitney Tew
NPI 1205268810
$114,197.10
in general payments reported to CMS, 2019-2025
37 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,772 · 2020: $2,191 · 2021: $12K · 2022: $2,150 · 2023: $16K · 2024: $65K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $96K · Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $95,832.60 |
| Food and Beverage | $731.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $95,832.60 | 2023-2025 | |
| Novo Nordisk INC | $12,010.46 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $1,325.07 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $554.57 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $527.89 | 2019-2025 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.88 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $397.20 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $369.82 | 2019-2022 | |
| Allergan, INC. | $340.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $300.70 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $243.35 | 2019-2023 | Livalo |
| Pfizer INC. | $222.44 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.98 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $187.96 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $182.86 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $153.24 | 2022 | |
| Sanofi-Aventis U.S. LLC | $97.68 | 2019-2020 | |
| Ibsa Pharma INC. | $91.26 | 2020-2024 | Tirosint, Licart |
| Dexcom, INC. | $88.37 | 2021-2022 | |
| Glaxosmithkline, LLC. | $74.09 | 2020-2023 | Trelegy Ellipta |
| Vivus LLC | $67.14 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $55.17 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.87 | 2021 | |
| Daiichi Sankyo INC. | $44.10 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $42.08 | 2021 | |
| Abbott Laboratories | $29.45 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $28.70 | 2019 | |
| Axsome Therapeutics, INC. | $27.11 | 2022 | |
| Eisai INC. | $26.44 | 2019 | |
| Astellas Pharma US INC | $22.65 | 2020 | |
| Biogen, INC. | $19.86 | 2022 | |
| Shire North American Group INC | $15.87 | 2019 | |
| Shield Therapeutics INC | $15.48 | 2023 | Accrufer |
| Currax Pharmaceuticals LLC | $15.20 | 2021 | |
| Genentech USA, INC. | $14.63 | 2021 | |
| Bausch Health US, LLC | $14.61 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Tew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.